Mechanism of Action
TREK-1 Channel Blockade
TREK-1 (KCNK2) is a two-pore domain K+ channel expressed throughout the CNS, particularly in serotonergic raphe neurons and hippocampal circuits. Channel opening hyperpolarizes neurons and reduces serotonin release. Spadin binds to the TREK-1 extracellular domain and blocks channel activity, preventing hyperpolarization and augmenting serotonergic transmission without directly affecting monoamine reuptake or synthesis.
Neuroplasticity Effects
Beyond acute serotonin enhancement, spadin treatment in animal models promotes hippocampal neurogenesis and upregulates BDNF expression. These neuroplastic changes are thought to underlie sustained behavioral improvements beyond the initial TREK-1 blockade, paralleling the delayed neuroplastic effects of conventional antidepressants.
Research Summary
Antidepressant Animal Models
AnimalSpadin produced antidepressant effects in forced swim test and tail suspension test models at doses of 1-4 mg/kg. Critically, effects appeared within days rather than weeks, suggesting faster onset than conventional antidepressants. In chronic mild stress models, spadin reversed anhedonia and normalized HPA axis reactivity.
Hippocampal Neurogenesis
AnimalSpadin treatment increased BrdU-positive proliferating cells in the dentate gyrus and upregulated BDNF protein in hippocampal tissue. These neurogenic effects correlated with persistent behavioral improvements and align with the neurogenesis theory of antidepressant action.
Calculate your Spadin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Antidepressant research | 1-4 mg/kg | Daily x 2-4 weeks | Subcutaneous |
All protocols are from animal studies. No human dosing data exists.
Interactions
Safety Profile
Animal studies show no significant adverse effects at effective doses. No sedation, catalepsy, or motor impairment was observed, contrasting with some conventional antidepressants. The endogenous origin of spadin, derived from sortilin processing, suggests compatibility with normal physiology. No human safety data exists.
References
- [1]Mazella J, et al. The Endogenous Nature and Potential Antidepressant Properties of Spadin. J Pharmacol Exp Ther. 2010.
- [2]Borsotto M, et al. Targeting Two-Pore Domain K+ Channels TREK-1 and TASK-3 for the Treatment of Depression. Front Pharmacol. 2015.
- [3]Devader C, et al. In vitro and in vivo antidepressant activities of the novel TREK-1 blocker spadin. Br J Pharmacol. 2012.